MedCity News November 28, 2023
SpringWorks Therapeutics drug Ogsiveo is now FDA-approved for treating desmoid tumors, a type of tumor affecting connective tissue. The regulatory decision makes the pill the first therapy approved specifically for treating this rare disorder.
A SpringWorks Therapeutics drug has won FDA approval for treating a rare type of connective tissue tumor, making it the first approved therapy for this rare type of tumor. It’s also the first product approval for the Pfizer spinout.
Desmoid tumors are soft tissue tumors that develop in connective tissue. They’re related to cancers of connective tissue called sarcomas, but are not considered cancerous because they do not spread throughout the body. However, desmoid tumors can be locally aggressive, invading surrounding healthy tissues such as joints,...
Today's Sponsors
Today's Sponsor